MXPA05008394A - Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma. - Google Patents
Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma.Info
- Publication number
- MXPA05008394A MXPA05008394A MXPA05008394A MXPA05008394A MXPA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A
- Authority
- MX
- Mexico
- Prior art keywords
- glaucoma
- diagnosis
- diabetic neuropathy
- cataract
- cataracts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/166—Cataract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10305212A DE10305212A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
PCT/EP2004/001048 WO2004069258A2 (de) | 2003-02-07 | 2004-02-05 | Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05008394A true MXPA05008394A (es) | 2005-10-05 |
Family
ID=32730900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05008394A MXPA05008394A (es) | 2003-02-07 | 2004-02-05 | Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1663246A2 (ru) |
JP (1) | JP2006519189A (ru) |
KR (1) | KR20050114214A (ru) |
CN (1) | CN1771039A (ru) |
AU (1) | AU2004210416A1 (ru) |
BR (1) | BRPI0407300A (ru) |
CA (1) | CA2514703A1 (ru) |
DE (1) | DE10305212A1 (ru) |
MX (1) | MXPA05008394A (ru) |
PL (1) | PL378399A1 (ru) |
RU (1) | RU2005127808A (ru) |
WO (1) | WO2004069258A2 (ru) |
ZA (1) | ZA200506280B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094796A2 (en) * | 2004-03-11 | 2005-10-13 | Merck Patent Gmbh | Methods for interfering with fibrosis |
US20070191326A1 (en) * | 2004-03-11 | 2007-08-16 | Florian Lang | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
WO2007037560A1 (ja) * | 2005-09-30 | 2007-04-05 | Link Genomics, Inc. | Sgk2遺伝子の治療的又は診断的用途 |
EP1957986B1 (en) * | 2005-11-22 | 2017-05-24 | McGill University | Intraocular pressure-regulated early genes and uses thereof |
WO2008079980A1 (en) * | 2006-12-22 | 2008-07-03 | Alcon Research, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
US9012161B2 (en) * | 2011-01-25 | 2015-04-21 | Monell Chemical Senses Center | Methods of identifying molecules that provide or enhance sweet taste |
KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006863A1 (en) * | 1994-08-30 | 1996-03-07 | University Of Dundee | Agents for inducing apoptosis and applications of said agents in therapy |
EP0832295A1 (en) * | 1995-06-07 | 1998-04-01 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists and antagonists |
US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
AU3991499A (en) * | 1998-05-15 | 1999-12-06 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
WO2000035946A1 (en) * | 1998-12-14 | 2000-06-22 | The University Of Dundee | Methods |
US6399655B1 (en) * | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
WO2001004145A2 (en) * | 1999-07-14 | 2001-01-18 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305212A patent/DE10305212A1/de not_active Withdrawn
-
2004
- 2004-02-05 MX MXPA05008394A patent/MXPA05008394A/es unknown
- 2004-02-05 WO PCT/EP2004/001048 patent/WO2004069258A2/de active Search and Examination
- 2004-02-05 CN CNA2004800070348A patent/CN1771039A/zh active Pending
- 2004-02-05 JP JP2006501737A patent/JP2006519189A/ja active Pending
- 2004-02-05 AU AU2004210416A patent/AU2004210416A1/en not_active Abandoned
- 2004-02-05 CA CA002514703A patent/CA2514703A1/en not_active Abandoned
- 2004-02-05 PL PL378399A patent/PL378399A1/pl not_active Application Discontinuation
- 2004-02-05 RU RU2005127808/15A patent/RU2005127808A/ru not_active Application Discontinuation
- 2004-02-05 BR BR0407300-2A patent/BRPI0407300A/pt not_active IP Right Cessation
- 2004-02-05 KR KR1020057014582A patent/KR20050114214A/ko not_active Application Discontinuation
- 2004-02-05 EP EP04708350A patent/EP1663246A2/de not_active Withdrawn
-
2005
- 2005-08-05 ZA ZA200506280A patent/ZA200506280B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0407300A (pt) | 2006-02-07 |
KR20050114214A (ko) | 2005-12-05 |
ZA200506280B (en) | 2006-05-31 |
WO2004069258A2 (de) | 2004-08-19 |
CA2514703A1 (en) | 2004-08-19 |
AU2004210416A1 (en) | 2004-08-19 |
RU2005127808A (ru) | 2006-05-27 |
PL378399A1 (pl) | 2006-04-03 |
CN1771039A (zh) | 2006-05-10 |
JP2006519189A (ja) | 2006-08-24 |
DE10305212A1 (de) | 2004-08-19 |
EP1663246A2 (de) | 2006-06-07 |
WO2004069258A3 (de) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mangold et al. | Sexually divergent induction of microglial-associated neuroinflammation with hippocampal aging | |
Bredel et al. | Tumor necrosis factor-α–induced protein 3 as a putative regulator of nuclear factor-κB–mediated Resistance to O6-alkylating agents in human glioblastomas | |
Kang et al. | Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal | |
Hattori et al. | Demyelinating and axonal features of Charcot–Marie–Tooth disease with mutations of myelin‐related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients | |
Tanaka et al. | Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system | |
Griffin et al. | The ribosome biogenesis factor Nol11 is required for optimal rDNA transcription and craniofacial development in Xenopus | |
EP2820131A2 (de) | Verwendung von micrornas oder genen als marker zur identifizierung, diagnose und therapie einzelner formen nicht-ischämischer kardiomyopathien oder speichererkrankungen des herzens | |
Scholz et al. | Dependency of intraocular pressure elevation and glaucomatous changes in DBA/2J and DBA/2J-Rj mice | |
MXPA05008394A (es) | Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma. | |
WO2005067391A3 (en) | Diagnostic test for parkinson's disease | |
Lynch et al. | Plasma biomarkers of reticular pseudodrusen and the risk of progression to advanced age-related macular degeneration | |
Kosior-Jarecka et al. | MicroRNAs in the aqueous humor of patients with different types of glaucoma | |
EP2463372B1 (en) | Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same | |
JP7244437B2 (ja) | 円錐角膜に関連する対立遺伝子を検出する方法 | |
Bua et al. | Diagnostic markers for glaucoma: a patent and literature review (2013-2019) | |
US20180318285A1 (en) | Methods for treatment of autism spectrum disorders | |
Wang et al. | Dysregulation of antimicrobial peptide expression distinguishes Alzheimer’s disease from normal aging | |
CN108354944A (zh) | siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用 | |
Ambler et al. | Microarray expression profiling in adhesion and normal peritoneal tissues | |
Rampazzo et al. | Hormographiella aspergillata keratomycosis in a dog | |
Truby et al. | A zinc finger transcription factor tunes social behaviors by controlling transposable elements and immune response in prefrontal cortex | |
Saddala et al. | RNA-seq data from CXC chemokine receptor type 5 (CXCR5) gene knockout aged mice with retinal degeneration phenotype | |
Shastry | Emerging concept of genetic and epigenetic contribution to the manifestation of glaucoma | |
Jo et al. | Gene expression profiles of primary retinal pigment epithelial cells from apolipoprotein E knockout and human apolipoprotein E2 transgenic mice | |
Li et al. | Divergent impacts of C9orf72 repeat expansion on neurons and glia in ALS and FTD |